Methotrexaat Teva (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, which is essential for converting folate into its active form. This interruption reduces the synthesis of DNA, RNA, and proteins, limiting the growth of rapidly dividing cells such as immune cells and cancer cells, and also triggers anti‑inflammatory pathways.

The dose of Methotrexaat Teva is individualized by the prescribing clinician based on the specific indication, patient weight, renal and hepatic function, and treatment response. Only a qualified healthcare professional should determine the appropriate dosing regimen.

Methotrexate is known to be teratogenic and is generally contraindicated during pregnancy. Women of child‑bearing potential should use effective contraception. Limited data exist for breastfeeding, and the drug may pass into breast milk, so use is usually avoided unless the benefit outweighs the risk.

To request Methotrexaat Teva, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Methotrexaat Teva is a first‑line disease‑modifying antirheumatic drug (DMARD) with a well‑established efficacy profile. Compared with biologic DMARDs, it is less expensive and administered via injection, but it may require more laboratory monitoring for hepatic and hematologic safety.

Methotrexaat Teva should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use to maintain stability and potency.

Methotrexaat Teva is supplied as a sterile injectable solution and can be given by epidural, intra‑articular or intramuscular injection, depending on the clinical indication and prescribing physician’s instructions.

The most serious risks include severe liver toxicity, pulmonary fibrosis, life‑threatening bone‑marrow suppression, acute kidney injury, and serious infections. Patients should be monitored regularly for signs of these complications, and therapy should be stopped if they occur.

Methotrexaat Teva is contraindicated in patients with known hypersensitivity to methotrexate, severe liver disease, significant renal impairment, active infections, and in pregnant women unless no alternative exists. Caution is also advised for individuals with pre‑existing blood disorders.